CHB患者疾病进程与抑郁症的程度及血清BDNF水平的相关性

被引:9
|
作者
惠凌云 [1 ]
王凌 [1 ]
张琳 [1 ]
冯艾 [1 ]
李娜 [1 ]
李义平 [2 ]
王亚文 [1 ]
机构
[1] 西安交通大学医学院第一附属医院检验科
[2] 西安交通大学药学院
关键词
慢性乙型肝炎; 抑郁症; 脑源性神经营养因子;
D O I
暂无
中图分类号
学科分类号
摘要
目的 研究慢性乙型肝炎(CHB)患者在疾病进展的不同阶段并发抑郁症的程度以及血清脑源性神经营养因子(BDNF)的水平。方法 选择HBV病毒携带者(ASC组)、肝硬化(LC组)和肝癌(HCC组)不同病程的患者126例和40例正常对照为研究对象,采用调查问卷调查研究对象人口学资料,以汉密尔顿抑郁量表(HAMD-17)进行评分和抑郁分级,同时采用ELISA法检测血清BDNF水平。结果 LC组、HCC组离异或丧偶的比率高于对照组(X2=6.354,11.972;P值均<0.01);ASC组、LC组、HCC组抑郁严重程度的分布均高于对照组,差异有统计学意义(X2=16.151,42.150,49.636;P值均<0.01);同时,ASC组抑郁严重程度低于LC组和HCC组,差异有统计学意义(X2=14.345,28.772;P值均<0.01);ASC,LC,HCC和对照组BDNF(x±s,ng/ml),分别为11.10±3.26,8.66±3.11,7.39±2.52和12.18±2.59,LC组和HCC组血清BDNF水平显著低于ASC组和对照组,差异有统计学意义(P值均<0.01);CHB病程的进展与HAMD评分存在正相关关系(r=0.719,P<0.01),与BDNF水平存在负相关关系(r=-0.504,P<0.01);血清BDNF水平与HAMD评分存在负相关关系(r=-0.526,P<0.01)。结论 CHB疾病的进程可使抑郁的程度加重,BDNF水平逐渐降低。提示血清BDNF水平可作为CHB患者心理治疗的实验室参考依据。有望提高临床医生对CHB患者伴随抑郁症发生的识别,提高诊疗效果。
引用
收藏
页码:13 / 16
页数:4
相关论文
共 10 条
  • [1] 核苷(酸)类似物抗病毒治疗对慢性乙型肝炎患者细胞免疫功能的影响.[J].陈宇;邱隆敏;姚新生;庄勤建;吕红;.世界华人消化杂志.2012, 35
  • [2] 慢性乙型肝炎患者抑郁症状对其社会支持状况的影响
    徐灿丽
    陈虹
    李岩
    侯志文
    张艳华
    李春梅
    [J]. 中华护理杂志, 2009, 44 (04) : 350 - 352
  • [3] Rutin activates the MAPK pathway and BDNF gene expression on beta-amyloid induced neurotoxicity in rats
    Moghbelinejad, Sahar
    Nassiri-Asl, Marjan
    Farivar, Taghi Naserpour
    Abbasi, Esmail
    Sheikhi, Mehdi
    Taghiloo, Mina
    Farsad, Farzaneh
    Samimi, Amir
    Hajiali, Farid
    [J]. TOXICOLOGY LETTERS, 2014, 224 (01) : 108 - 113
  • [4] Snapin Recruits Dynein to BDNF-TrkB Signaling Endosomes for Retrograde Axonal Transport and Is Essential for Dendrite Growth of Cortical Neurons
    Zhou, Bing
    Cai, Qian
    Xie, Yuxiang
    Sheng, Zu-Hang
    [J]. CELL REPORTS, 2012, 2 (01): : 42 - 51
  • [5] Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression
    Dreimueller, Nadine
    Schlicht, Konrad Friedrich
    Wagner, Stefanie
    Peetz, Dirk
    Borysenko, Liudmyla
    Hiemke, Christoph
    Lieb, Klaus
    Tadic, Andre
    [J]. NEUROPHARMACOLOGY, 2012, 62 (01) : 264 - 269
  • [6] Correlations between brain-derived neurotrophic factor and clinical symptoms in medicated patients with major depression.[J].Emi Satomura;Hajime Baba;Yoshiyuki Nakano;Hitoshi Maeshima;Toshihito Suzuki;Heii Arai.Journal of Affective Disorders.2011, 1
  • [7] Decreased BDNF, trkB-TK+ and GAD^sub 67^ mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders.[J].Ray, Mia Thompson;Weickert, Cynthia Shannon;Wyatt, Eugene;Webster, Maree J.Journal of Psychiatry & Neuroscience : JPN.2011, 3
  • [8] Effects of recognizing depression with a standardized questionnaire (CES-D) versus patient reporting of depression after a single-standardized question on the outcomes of treatment for hepatitis C with pegylated interferon-α-2b and ribavirin
    Phillips, Frances H.
    Prebis, Melanie
    Grumbeck, Catherine
    Hale, Teresa
    Cubillas, Raul
    Brown, Geri R.
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (12) : 1435 - 1442
  • [9] Depression and immunity: A role for T cells?.[J].Andrew H. Miller.Brain Behavior and Immunity.2009, 1
  • [10] Neuroprotection by Imipramine against lipopolysaccharide-induced apoptosis in hippocampus-derived neural stem cells mediated by activation of BDNF and the MAPK pathway.[J].Chi-Hsien Peng;Shih-Hwa Chiou;Shih-Jen Chen;Yueh-Ching Chou;Hung-Hai Ku;Cheng-Kuo Cheng;Chih-Ju Yen;Tung-Hu Tsai;Yuh-Lih Chang;Chun-Lan Kao.European Neuropsychopharmacology.2007, 2